뒤로
Starpharma Holdings Ltd(SPHRY) 가격
SPHRY 주가 차트
SPHRY 수입
Starpharma Holdings Ltd
$2.3
-11.53%
$-0.3
종가: Jan 16, 16:00:00 GMT-5
$2.3
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
주요 통계
이전 종가
$2.6
시가
$2.3
일일 범위
$2.3 - $2.3
52주 범위
$0.47 - $2.86
거래량
1.1K
평균 거래량
1.0K
EPS(TTM)
-0.16
배당수익률
--
시가총액
$96.1M
SPHRY란 무엇인가요?
Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. The firm's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The firm's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. The company also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The firm has applied its DEP technology to the innovative area of antibody-drug conjugates.